The Gilead Sciences Inc. (GILD) Stake Cut by Argent Trust Co

The Gilead Sciences Inc. (GILD) Stake Cut by Argent Trust Co

Argent Trust Co decreased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 13.1% during the third quarter, Holdings Channel reports. The institutional investor owned 17,443 shares of the biopharmaceutical company’s stock after selling 2,636 shares during the period. Argent Trust Co’s holdings in Gilead Sciences were worth $1,380,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Old Mutual Global Investors UK Ltd. boosted its stake in shares of Gilead Sciences by 256.3% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 1,156,623 shares of the biopharmaceutical company’s stock valued at $96,485,000 after buying an additional 832,028 shares during the last quarter. Gilman Hill Asset Management LLC boosted its stake in shares of Gilead Sciences by 3.2% in the second quarter. Gilman Hill Asset Management LLC now owns 2,960 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 92 shares during the last quarter. Botty Investors LLC acquired a new stake in shares of Gilead Sciences during the second quarter valued at approximately $1,668,000. CWM LLC boosted its stake in shares of Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares during the last quarter. Finally, JLB & Associates Inc. boosted its stake in shares of Gilead Sciences by 4.2% in the second quarter. JLB & Associates Inc. now owns 117,323 shares of the biopharmaceutical company’s stock valued at $9,787,000 after buying an additional 4,702 shares during the last quarter. Hedge funds and other institutional investors own 73.46% of the company’s stock.

Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.78% during trading on Thursday, hitting $71.57. The stock had a trading volume of 9,809,269 shares. The stock has a market capitalization of $94.29 billion, a P/E ratio of 6.62 and a beta of 1.20. Gilead Sciences Inc. has a 52 week low of $70.83 and a 52 week high of $103.10. The company has a 50-day moving average of $73.69 and a 200-day moving average of $77.47.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The firm earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. During the same period in the prior year, the business earned $3.22 earnings per share. The business’s quarterly revenue was down 9.6% compared to the same quarter last year. On average, equities analysts expect that Gilead Sciences Inc. will post $11.47 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th were given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date was Tuesday, December 13th. Gilead Sciences’s dividend payout ratio is currently 17.44%.

GILD has been the topic of several research analyst reports. Jefferies Group increased their target price on Gilead Sciences from $91.00 to $93.00 and gave the stock a “buy” rating in a report on Wednesday, October 5th. RBC Capital Markets reiterated a “buy” rating and issued a $95.00 price target (down previously from $105.00) on shares of Gilead Sciences in a report on Monday, October 3rd. Gabelli reiterated a “buy” rating on shares of Gilead Sciences in a report on Friday, September 23rd. Leerink Swann set a $112.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, September 22nd. Finally, Piper Jaffray Cos. set a $108.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Thursday, September 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $96.44.

In other news, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the transaction, the insider now directly owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Related posts

Leave a Comment